There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through ...

Are you a print subscriber? Activate your account. 25 min 43 sec ago By Rod Sobral - 3 hours 7 min ago By Tim Nudd - 3 hours 7 min ago By Erika Wheless - 3 hours 37 min ago By Garett Sloane - 3 ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

A new alliance between Sanofi and Google has been launched to improve care in people with type 1 and type 2 diabetes, the latest in a growing number of tie-ups between pharma and technology companies.

Ventyx Biosciences, Inc. ( (VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors. Ventyx Biosciences, Inc. is a clinical ...

A webcast of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after ...

Ventyx Biosciences (NASDAQ:VTYX – Get Free Report)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports.

Oppenheimer reiterated their outperform rating on shares of Ventyx Biosciences (NASDAQ:VTYX – Free Report) in a report issued on Friday morning,Benzinga reports. Oppenheimer currently has a $9. ...